15-epi Bimatoprost CAS NO.1163135-92-9

During the production of bimatoprost, 15-epi bimatoprost is often produced, which involves the isomerization of the 15th carbon atom in the bimatoprost molecule. Subsequently, this intermediate is further converted to eventually form bimatoprost. bimatoprost is classified as a synthetic prostamide F2α analog, and its effectiveness in lowering intraocular pressure (IOP), as well as its superiority in maintaining 24-hour control, is well established as the most effective treatment for intraocular hypertensive disorders, including glaucoma. Through the activation of prostaglandins and prostaglandin-like receptors, bimatoprost is constantly being developed for new applications and directions in the biomedical field.

Bimatoprost reduces IOP by increasing aqueous outflow from trabecular meshwork channels and uveoscleral channels and decreasing superficial scleral venous pressure. this is the basis and mechanism for the use of bimatoprost in the treatment of glaucoma and high intraocular pressure (IOP) diseases.
Based on the application in the field of ocular diseases, bimatoprost has been found to have the side effect of abnormal hair growth. Utilizing this side effect, bimatoprost was developed for use in hair growth preparations, such as eyelash growth solutions, hair loss, etc. It is used in the treatment of glaucoma and hyperopia. It promotes hair growth, thickening, and darkening by promoting the hair into the anagen phase and prolonging the anagen phase.
Bimatoprost has been used in the study of hypopigmentation disorders (vitiligo, etc.) basing on the side effect of hyperpigmentation of the skin caused by bimatoprost. Bimatoprost promotes increased melanin production to induce hyperpigmentation around the eyes, providing better repigmentation. However, the whole process is not accompanied by melanocyte proliferation, cellular anisotropy or inflammatory response.
Bimatoprost may also have potential for periorbital rejuvenation. In one study, topical bimatoprost applied to the periorbital area was found to improve skin laxity in both the upper and lower eyelid areas, with a significant loss of the lower eyelid fat pad and firmer skin. Bimatoprost's ability to improve the appearance of the entire periorbital area may even lead to chemical oculoplastic effects in the future.